Tatva Chintan Pharma Chem Ltd

  • BSE Code : 543321
  • NSE Symbol : TATVA
  • ISIN : INE0GK401011
  • Industry :CHEMICALS

up-arrow 900.80 -35.45(-3.79%)

Open Price ()

935.00

Prev. Close ()

936.25

Volume (No’s)

46,660

Market Cap ()

2,190.08

Low Price ()

896.10

High Price ()

942.90

 

Book Closure

From Date To Date Announcement
02-May-2025 NA Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2025 inter alia to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2025; 2. consider and recommend a final dividend if any on the equity shares of the Company for the financial year ended 31 March 2025 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 April 2025 till the expiry of 48 hours from the date the said financial results are made public. Outcome of the Board Meeting held on 02.05.2025. (As per BSE Announcement Dated on 02/05/2025)
31-Mar-2025 NA Outcome of Board Meeting - Board approves Dividend The Board Recommended a Final Dividend of Rs. 1/- (10%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 23,39,20,550/- (2,33,92,055 equity shares of Rs. 10/- each) for the financial year 2024-25. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company
28-Jan-2025 NA Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2024. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 January 2025 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31 December 2024 Outcome of the Board Meeting held on 28.01.2025 (As Per BSE Announcement dated on 28.01.2025)
25-Oct-2024 NA Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2024. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 October 2024 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take the above intimation on your record and oblige. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30 September 2024 (As Per BSE Announcement dated on 25.10.2024)
20-Sep-2024 NA AGM 20/09/2024 Summary of proceedings of the 28th Annual General Meeting held on Friday, 20 September 2024 (As Per BSE Announcement Dated on: 20/09/2024) Scrutinizer''s Report / Voting Results of 28th Annual General Meeting of the Company held on Friday, 20 September 2024 (As Per BSE Announcement dated on 21.09.2024)

Copyright © 2024 Arihant Capital Markets Ltd. All rights Reserved.

Designed,Developed and Content powered by CMOTS Infotech (ISO 9001:2015 certified)

x
  • QR-CodeNew